Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience

Emiliano Barbieri; Monica Maccaferri; Giovanna Leonardi; Francesca Giacobbi; Giorgia Corradini; Ivana Lagreca; Patrizia Barozzi; Leonardo Potenza; Roberto Marasca; Mario Luppi

doi:10.1007/s00277-022-04978-6

Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience

Ann Hematol. 2022 Dec;101(12):2777-2779. doi: 10.1007/s00277-022-04978-6. Epub 2022 Sep 15.

Affiliations

¹ Hematology Unit and Chair, Azienda Ospedaliera Universitaria Di Modena and Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy. emilianobarbieri33@gmail.com.
² Hematology Unit and Chair, Azienda Ospedaliera Universitaria Di Modena and Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.

^# Contributed equally.

No abstract available

Keywords: Chromosome 1q amplification; Chromosome 1q gain/amplification; Daratumumab; Multiple myeloma; Relapsed-refractory multiple myeloma; To the editor.

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Chromosomes
Humans
Multiple Myeloma* / drug therapy
Multiple Myeloma* / genetics
Neoplasms, Plasma Cell*
Retrospective Studies

Substances

daratumumab

Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience

Authors

Affiliations

Publication types

MeSH terms

Substances

Grants and funding